New Releases from NCBI BookshelfAlectinib (Alecensaro): Indication: For adjuvant treatment following tumour resection for patients with stage IB (tumour ≥ 4 cm) to IIIA ALK-positive non–small cell lung cancer: Reimbursement Recommendation [Internet].​Alectinib (Alecensaro): Indication: For adjuvant treatment following tumour resection for patients with stage IB (tumour ≥ 4 cm) to IIIA ALK-positive non–small cell lung cancer: Reimbursement Recommendation [Internet].